Stephen M Zappala
Overview
Explore the profile of Stephen M Zappala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattu A, Zappala S, Parekh D, Punnen S
Urology
. 2020 Nov;
148:53-58.
PMID: 33217456
Objective: To evaluate the 4Kscore test's low risk cut-off of 7.5% as the indication to proceed with a prostate biopsy by combining data from 2 independent prospective multicentre trials in...
2.
Albala D, Manak M, Varsanik J, Rashid H, Mouraviev V, Zappala S, et al.
Urology
. 2018 Oct;
124:198-206.
PMID: 30312670
Objective: To examine the ability of a novel live primary-cell phenotypic (LPCP) test to predict postsurgical adverse pathology (P-SAP) features and risk stratify patients based on SAP features in a...
3.
Zappala S, Scardino P, Okrongly D, Linder V, Dong Y
Rev Urol
. 2018 Jan;
19(3):149-155.
PMID: 29302237
The 4Kscore Test (OPKO Diagnostics, Woburn, MA) is a blood test utilized prior to a prostate biopsy to determine a patient's risk of high-grade prostate cancer (PCa) should the biopsy...
4.
5.
Punnen S, Nahar B, Prakash N, Sjoberg D, Zappala S, Parekh D
Eur Urol Focus
. 2017 Jul;
3(1):94-99.
PMID: 28720374
Background: The 4Kscore accurately predicts aggressive prostate cancer (PCa) on prostate biopsy. Objective: We assessed how well the 4Kscore predicts pathology at radical prostatectomy (RP). Design, Setting, And Participants: Among...
6.
Zappala S, Dong Y, Linder V, Reeve M, Sjoberg D, Mathur V, et al.
Int J Clin Pract
. 2017 May;
71(6).
PMID: 28497893
Introduction: The 4Kscore Test is a prebiopsy blood test that incorporates four prostate protein biomarkers along with patient clinical information to determine a man's risk for high-grade, aggressive (Gleason ≥7)...
7.
Chander A, Manak M, Varsanik J, Hogan B, Mouraviev V, Zappala S, et al.
Urology
. 2017 Apr;
105:91-100.
PMID: 28365358
Objective: To culture prostate cells from fresh biopsy core samples from radical prostatectomy (RP) tissue. Further, given the genetic heterogeneity of prostate cells, the ability to culture single cells from...
8.
Konety B, Zappala S, Parekh D, Osterhout D, Schock J, Chudler R, et al.
Rev Urol
. 2016 Feb;
17(4):231-40.
PMID: 26839521
There is significant concern regarding prostate cancer screening because of the potential for overdiagnosis and overtreatment of men who are discovered to have abnormal prostate specific antigen (PSA) levels and/or...
9.
Parekh D, Punnen S, Sjoberg D, Asroff S, Bailen J, Cochran J, et al.
Eur Urol
. 2014 Dec;
68(3):464-70.
PMID: 25454615
Background: The 4Kscore combines measurement of four kallikreins in blood with clinical information as a measure of the probability of significant (Gleason ≥7) prostate cancer (PCa) before prostate biopsy. Objective:...
10.
Voigt J, Zappala S, Vaughan E, Wein A
Prostate
. 2013 Oct;
74(3):250-9.
PMID: 24166488
Background: Current diagnostic testing for prostate cancer results in numerous unnecessary biopsy procedures and creates a substantial financial burden. A statistical prediction model for prostate cancer has been developed, based...